psoriasis Archives -

Almirall-backed psoriasis support app Claro launches in Europe

Phil Taylor Almirall, dermatology, digital, digital health, Happify, mental health, patient support, psoriasis 0 Comment

An alliance between Spanish drugmaker Almirall and digital health company Happify has yielded its first fruit, with the

Almirall-backed psoriasis support app Claro launches in Europe

https://pharmaphorum.com/news/almirall-backed-psoriasis-support-app-claro-launches-in-europe/

Market Access/ News/ News

Dermavant claims its first approval as FDA clears psoriasis drug

Phil Taylor dermatology, Dermavant, psoriasis, regulatory approval, tapinarof, Vtama 0 Comment

Roivant group company Dermavant has made the transition to a commercial-stage company after getting FDA approval for Vtama,

Dermavant claims its first approval as FDA clears psoriasis drug

https://pharmaphorum.com/news/dermavant-claims-its-first-approval-as-fda-clears-psoriasis-drug/

Market Access/ News/ News

FDA rejects UCB’s psoriasis therapy bimekizumab

Phil Taylor bimekizumab, fda, psoriasis, regulatory, UCB 0 Comment

The FDA has delivered a blow to UCB’s late-stage pipeline, after saying it is unable to approve its

FDA rejects UCB’s psoriasis therapy bimekizumab

https://pharmaphorum.com/news/fda-rejects-ucbs-psoriasis-therapy-bimekizumab/

Digital/ News/ News

Happify says study backs value of its wellbeing app in psoriasis

Phil Taylor app, dermatology, digital, digital health, Happify, mental health, psoriasis 0 Comment

People with psoriasis who used an app developed by digital health company Happify reported reduced anxiety and improvements

Happify says study backs value of its wellbeing app in psoriasis

https://pharmaphorum.com/news/happify-says-study-backs-value-of-its-wellbeing-app-in-psoriasis/

News/ News/ Sales and Marketing

Amgen builds Otezla’s psoriasis label as rival BMS looms large

Phil Taylor Amgen, Bristol-Myers Squibb, deucravacitinib, Otezla, psoriasis, sales & marketing 0 Comment

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it

Amgen builds Otezla’s psoriasis label as rival BMS looms large

https://pharmaphorum.com/news/amgen-builds-otezlas-psoriasis-label-as-rival-bms-looms-large/

Market Access/ News/ News

FDA sets Sept review date for BMS’ psoriasis drug deucravacitinib

Phil Taylor Amgen, Bristol-Myers Squibb, deucravacitinib, Immunology and inflammation, Otezla, psoriasis 0 Comment

The FDA has kicked off its review of Bristol-Myers Squibb’s psoriasis therapy deucravacitinib, setting an action date of

FDA sets Sept review date for BMS’ psoriasis drug deucravacitinib

https://pharmaphorum.com/news/fda-sets-sept-review-date-for-bms-psoriasis-drug-deucravacitinib/

Partner content/ Partner Content/ Press releases

Patient and market insights from leading KOLs and life science leaders

Fishawack Marketing dermatology, market access, patient access, portfolio strategy, psoriasis 0 Comment

Insights from leading KOLs in new Dermatology eBook

Patient and market insights from leading KOLs and life science leaders

https://pharmaphorum.com/partner-content/patient-and-market-insights-from-leading-kols-and-life-science-leaders/

Market Access/ News/ News

NICE backs Cosentyx’ use in thousands of children with psoriasis

Phil Taylor Cosentyx, HEOR, market access, NHS, NICE, Novartis, paediatric, psoriasis 0 Comment

NICE has recommended broadening NHS use of Novartis’ IL-17 inhibitor Cosentyx to include children aged six to 17

NICE backs Cosentyx’ use in thousands of children with psoriasis

https://pharmaphorum.com/news/nice-backs-cosentyx-use-in-thousands-of-children-with-psoriasis/

Market Access/ News/ News

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

Phil Taylor bimekizumab, Bimzelx, Cosentyx, dermatology, EU, Novartis, psoriasis, regulatory approval, UCB 0 Comment

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

https://pharmaphorum.com/news/il-17-tailender-ucb-gets-eu-ok-for-bimekizumab-in-psoriasis/

Trending

psoriasis

Login